Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/09/26	SEK 13.60	+4.62%	6,244
04/09/26	SEK 13.00	-1.89%	17,195
03/09/26	SEK 13.25	-2.21%	4,505
02/09/26	SEK 13.55	+1.88%	60
01/09/26	SEK 13.30	-0.37%	1,895

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 20:00:00 07/09/2026 +04			5-day change	1st Jan Change
13.60 ^SEK	+4.62%		+2.26%	-31.31%

08-21	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate	MT

Market Cap	96M 10.01M 8.61M 8.1M 7.39M 13.82M 947M 13.87M 37.11M 485M 37.59M 36.77M 1.54B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	96M 10.01M 8.61M 8.1M 7.39M 13.82M 947M 13.87M 37.11M 485M 37.59M 36.77M 1.54B	EV / Sales 2026 *	2.07x	EV / Sales 2027 *	2.9x
Free-Float	54.31%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ANNX	Delayed
Deutsche Boerse AG	Q910	Delayed

08-21	Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Annexin Pharmaceuticals Expands Study on Retinal Vein Occlusion Drug Candidate	MT
08-21	Annexin Pharmaceuticals Advances the Nexus Study to Include Patients Who Received an Anti-Vegf Injection	CI
08-20	Annexin Pharmaceuticals AB Receives The International Nonproprietary Name Vanexin For The Drug Candidate ANXV	CI
07-21	Annexin Pharmaceuticals Updates on Nine Patients Treated in Nexus Study	CI
07-16	Calendar, Thursday, July 16	FW
06-23	Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo	CI
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW
06-09	Calendar Wednesday June 10	FW
05-21	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo	CI
05-11	Annexin receives German approval for ANXV clinical trial	RE
05-11	Annexin Pharmaceuticals AB Receives Clinical Trial Approval for ANXV in Germany, Widening Patient Recruitment in the Nexus Study	CI

Annexin Pharmaceuticals AB Stock

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation : Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news : Annexin Pharmaceuticals AB

Press Releases : Annexin Pharmaceuticals AB

News in other languages : Annexin Pharmaceuticals AB

Quotes and Performance

Price Extremes

Managers and Directors : Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

08-21	Annexin advances the NEXUS study to include patients who received an anti-VEGF injection	AQ
08-20	Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV	AQ
07-21	Annexin updates on nine patients treated in NEXUS study	AQ
07-03	Annexin's rights issue 98 percent subscribed	AQ
06-23	Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO	AQ

1 day	+4.62%
1 week	+2.26%
Current month	+1.87%
1 month	+10.57%
3 months	-0.73%
6 months	-6.21%
Current year	-31.31%

1 week	12.6	13.6
1 month	12.25	14.15
Current year	11.05	23.6
1 year	11.05	29.8
3 years	11.05	97.6
5 years	11.05	225
10 years	11.05	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	01/01/2019
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	01/01/2016
Susanne Andersson DFI	Director of Finance/CFO	55	11/04/2023

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	01/01/2017
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	01/01/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	+4.62%	+2.26%	-50.72%	-79.20%	9.59M
WUXI APPTEC CO., LTD.	-0.38%	-2.64%	+42.69%	+99.03%	67.98B
ARGENX SE	-2.71%	-2.88%	+35.89%	+80.22%	64.94B
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+377.83%	27.58B
BIONTECH SE	+0.86%	+1.65%	-7.74%	-13.58%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	-1.42%	-4.28%	+31.24%	+13.27%	25.74B
GENMAB A/S	-1.11%	-0.70%	+22.24%	-17.69%	20.09B
PHARMAESSENTIA CORPORATION	+1.15%	-14.24%	+219.82%	+381.14%	17.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.20%	-4.68%	-6.41%	+560.92%	14.92B
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+165.57%	14.62B
Average	+0.07%	+0.72%	+32.98%	+156.75%	27.91B
Weighted average by Cap.	-0.81%	+0.59%	+37.32%	+140.89%

	2026 *	2027 *
Net sales	46.3M 4.83M 4.15M 3.9M 3.56M 6.67M 457M 6.69M 17.9M 234M 18.13M 17.73M 745M	33.1M 3.45M 2.97M 2.79M 2.55M 4.77M 326M 4.78M 12.79M 167M 12.96M 12.68M 532M
Net income	-11.5M -1.2M -1.03M -970K -885K -1.66M -113M -1.66M -4.45M -58.07M -4.5M -4.4M -185M	-24.9M -2.6M -2.23M -2.1M -1.92M -3.59M -246M -3.6M -9.62M -126M -9.75M -9.54M -401M
Net Debt	-	-